Soleno Therapeutics Inc (SLNO)

In the past six months, Soleno Therapeutics' stock has experienced several notable events. The company reported strong third-quarter 2025 financial results, with earnings per share (EPS) of $0.47, significantly exceeding analysts' expectations, and net revenue more than doubled from the second quarter of 2025 to $66.0 million, achieving profitability with a net income of $26.0 million for the quarter. Despite these positive financial results, the stock declined by 2.89% in aftermarket trading on November 4, 2025, with concerns about demand for Vykat XR. In July 2025, the company raised $230 million in gross proceeds through an underwritten offering of common stock. As of February 4, 2026, Soleno Therapeutics' market capitalization had decreased by 10.28% in the last 30 days and 9.03% in the last 12 months. The stock opened at $42.12 on February 5, 2026, and has traded within a 1-year range of $37.95 to $90.32. On February 5, 2026, Zacks Research lowered Soleno Therapeutics' rating to "Hold." Short interest in SLNO increased by 4.97% as of January 15, 2026. On January 21, 2026, CEO Anish Bhatnagar reported new equity awards, including restricted stock units and stock options. The company announced preliminary fourth-quarter and full-year 2025 results on January 12, 2026. On January 5, 2026, Soleno Therapeutics announced the publication of results from a pivotal study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism. Soleno Therapeutics is scheduled to participate in several investor conferences in February and March 2026.

Given that Soleno Therapeutics' primary product, VYKAT™ XR, is a treatment for a rare genetic disorder like Prader-Willi syndrome, significant seasonality in product demand driven by typical consumer patterns is unlikely. The need for such a therapy is generally ongoing rather than fluctuating with seasons. While there is information indicating historical seasonality in the implied volatility of SLNO's stock, with volatility tending to rise in May and decline in August, this reflects market trading patterns rather than direct seasonality in the demand for the company's therapeutic product.

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases. Their lead product candidate, VYKAT™ XR (diazoxide choline extended-release tablets), is a once-daily oral tablet for treating hyperphagia in adults and children aged four years and older with Prader-Willi syndrome (PWS). VYKAT™ XR received FDA approval on March 26, 2025, and was expected to be available in the U.S. starting April 2025. The therapy has also been granted Breakthrough Therapy and Fast-Track designations in the United States, and Orphan Drug designations in both the United States and the European Union.

Soleno Therapeutics is headquartered in Redwood City, California, United States. Its primary commercial focus for VYKAT™ XR is currently the U.S. market, but clinical trials for DCCR have been conducted in both the U.S. and the U.K. The company's Orphan Drug designations in the European Union indicate potential future market expansion. The company's institutional ownership base is global, with shareholders from various countries.

Soleno Therapeutics' brand reputation has been shaped by the FDA approval of VYKAT™ XR, positive clinical trial results, and strong financial performance in Q3 2025. However, the stock's decline despite these strong earnings and a subsequent "Hold" rating from Zacks Research suggest that market sentiment and investor confidence may be influenced by factors beyond immediate financial performance.

Soleno Therapeutics, Inc. has a significant institutional ownership base, with 520 institutional owners holding a total of 72,763,218 shares. Major institutional shareholders include Fmr Llc, Janus Henderson Group Plc, Price T Rowe Associates Inc /md/, BlackRock, Inc., Vanguard Group Inc, Avoro Capital Advisors LLC, Wellington Management Group Llp, Vivo Capital, LLC, State Street Corp, and Invesco Ltd. Institutional investors increased their holdings from 137.29% to 138.54% in December 2025. Individual investors hold 2.31% of the shares, while insiders decreased their holdings from 1.99% to 1.74% in December 2025. As of January 21, 2026, CEO Anish Bhatnagar directly owned 583,656 shares of common stock and 131,400 stock options.